Currently, IL-6/IL-6R pathway inhibitors, such as tocilizumab, are predominantly utilised for their anti-inflammatory effects in autoimmune diseases, cytokine release syndrome, cancer-associated cachexia, and to enhance tolerance to immunotherapy [20,68]. The gene discussed is IL6R; the disease is Cachexia.